(Reuters)—The U.S. National Institutes of Health (NIH) is testing a booster shot of COVID-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course. The mid-stage study will be conducted among about 600 participants aged 18 and above who have been fully vaccinated with shots from either Pfizer Inc.,…
Kaitlyn Brittan, MD: ‘Advocacy Tells Me I Have a Voice’
Rheumatology advocacy added focus and purpose to Dr. Brittan’s medical training and now, in the rheumatology division at the University of Nebraska Medical Center, strengthens her relationships with colleagues and patients alike.
2-Year Extension Study Supports Voclosporin to Treat Patients with Lupus Nephritis
Research has shown voclosporin in combination with MMF and low-dose steroids benefits patients with lupus nephritis, significantly increasing the speed of remission. New data from an ongoing extension study demonstrate a positive risk/benefit profile.
Infections, Low IgG Seen in Kids Receiving Rituximab for Rheumatic Disease
NEW YORK (Reuters Health)—A significant proportion of children with rheumatic diseases develop new-onset hypogammaglobulinemia and infections following treatment with the monoclonal antibody rituximab, according to new U.S. research. “Increased risk appeared to be mediated, at least in part, by exposure to pulse dose corticosteroids,” write Marc Natter, MD, of Harvard Medical School and Boston Children’s…
EU Evaluates Tocilizumab as COVID-19 Treatment
(Reuters)—Europe’s drugs regulator said on Monday it was evaluating the use of Roche’s arthritis drug, tocilizumab, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment. Tocilizumab, sold by Roche as Actemra and RoActemra, has shown promise in clinical trials in treating COVID-19, and was approved by U.S. health regulators in…
International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
ACR Commends CMS Decision to Withdraw Most Favored Nation Payment Model for Part B Drugs
ATLANTA—The American College of Rheumatology (ACR) today applauded the U.S. Centers for Medicare & Medicaid Services’ (CMS) decision to withdraw a proposed rule to implement the “Most Favored Nation” (MFN) payment model for Part B drugs. Leaders felt the policy would have dramatically disrupted patient access to critical therapies needed to manage rheumatic diseases and…
Therapeutic Drug Monitoring May Offer Little Benefit to Patient Remission Rates During Infliximab Induction Therapy
Although rheumatologists prescribe tumor necrosis factor inhibitors (TNFi’s) to treat several rheumatic diseases, they recognize immunogenicity influences the efficacy and safety of TNFi’s. Example: The formation of anti-drug antibodies can affect infusion reactions and cause low-serum drug levels and therapeutic failure. The induction phase is a period of high incidence of immunogenicity, and observational data…
UHC Updates Policy on Reimbursement for Incident-to Services
On Aug. 1, UnitedHealthcare implemented a new policy on Services Incident-to a Supervising Health Care Provider that allows for appropriate reimbursement for “incident-to” services consistent with current Medicare guidelines.
Advocate at Home During the August Recess
With lawmakers home for the summer recess, you have the opportunity to meet with them in their local offices and help them understand how key legislation affects patients and healthcare providers. The ACR offers tools, resources and more to help.
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 332
- Next Page »